机译:AML中的最小/可测量的残留疾病:欧洲Leukemianet MRD工作组的共识文件
Vrije Univ Amsterdam Med Ctr Dept Hematol Boelelaan 1117 NL-1081 HV Amsterdam Netherlands;
Hannover Med Sch Dept Hematol Hemostasis Oncol &
Stem Cell Transpl Hannover Germany;
Univ Birmingham Coll Med &
Dent Sci Inst Immunol &
Immunotherapy Dept Clin Immunol Birmingham;
Univ Hosp Nantes Hematol Biol Nantes France;
Univ Roma Tor Vergata Dept Biomed &
Prevent Rome Italy;
Vrije Univ Amsterdam Med Ctr Dept Hematol Boelelaan 1117 NL-1081 HV Amsterdam Netherlands;
Kings Coll London Div Genet &
Mol Med London England;
MLL Munich Leukemia Lab Munich Germany;
Cardiff Univ Ctr Trials Res Cardiff S Glam Wales;
NIH Myeloid Malignancies Sect Bldg 10 Bethesda MD 20892 USA;
Univ Texas MD Anderson Canc Ctr Dept Hematopathol Lab Med Div Pathol Houston TX 77030 USA;
MLL Munich Leukemia Lab Munich Germany;
Univ Hosp Flow Cytometry Platform Bordeaux France;
Univ Roma Tor Vergata Dept Biomed &
Prevent Rome Italy;
Univ Hosp Lille Ctr Pathol Lab Hematol Lille France;
Radboud Univ Nijmegen Med Ctr Dept Lab Med Lab Hematol Nijmegen Netherlands;
Tech Univ Dresden Univ Klinikum Carl Gustav Garus Dresden Germany;
Univ Roma Tor Vergata Dept Biomed &
Prevent Rome Italy;
Univ Oxford Oxford Ctr Haematol Med Res Council Mol Haematol Unit Oxford England;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Univ Hosp Ulm Dept Internal Med 3 Ulm Germany;
Weill Cornell Med New York NY USA;
Vrije Univ Amsterdam Med Ctr Dept Hematol Boelelaan 1117 NL-1081 HV Amsterdam Netherlands;
机译:AML中的最小/可测量的残留疾病:欧洲Leukemianet MRD工作组的共识文件
机译:欧洲LeukemiaNet AML工作组关于异基因HSCT用于缓解期AML患者的共识声明:一种适应综合风险的方法
机译:可测量的残余疾病,调理方案强度和年龄预测急性髓性白血病的同种异体造血细胞移植的成因:2292名急性白血病欧洲血液和骨髓移植患者的注册表分析
机译:使用基于微流体分析的白血病患者最小残留疾病(MRD)的检测
机译:高灵敏度流式细胞术检测和监测多发性骨髓瘤可测量的残留疾病
机译:AML中最小/可测量的残留疾病:欧洲LeukemiaNet MRD工作组的共识文件
机译:抗胸腺细胞球蛋白(ATG)在同种异体干细胞移植时从兄弟姐妹和无关供体在CR1中移植的AML中的患者的作用:代表急性白血病工作组的研究欧洲血液和骨髓移植(EBMT)的(ALWP)